Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119263 | 0.92 | KMT2A (0.66) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.90 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31031901 | 0.87 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29468684 | 0.87 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL230688 | 0.87 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL28617673 | 0.87 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL6063328 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL23111835 | 0.86 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL17971325 | 0.86 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL1660910 | 0.86 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8512675-B2 | N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination | MALLINCKRODT LLC (US) | 2013-08-20 | — | — | US | disclosed |
| EP-1618380-B1 | N epsilon AND/OR N alpha DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH (M(OH2)3(CO)3)+ BY FAC COORDINATION | UNIV ZUERICH (CH) | 2009-12-30 | — | — | EP | disclosed |
| CN-100507563-C | N.epsilon. and/or n.alpha. derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3(co)3]+ by fac coordination | UNIV ZUERICH (CH) | 2009-07-01 | — | — | CN | disclosed |
| US-20070077195-A1 | \"N and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3 (co)3]+ by fac coordination\ | UNIVERSITY OF ZURICH (CH) | 2007-04-05 | — | — | US | disclosed |
| CN-1781021-A | N.epsilon. and/or n.alpha. derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3(co)3]+ by fac coordination | UNIV ZUERICH (CH) | 2006-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077195-A1 | \"N and/or nalpha derivatized, metal and organic protected l-histidine for coupling to biomolecules for highly efficient labeling with [m(oh2)3 (co)3]+ by fac coordination\ | CPN1, NUCB2, NAA15 | KMT2A 1591/4885EPHX2 1984/4885FABP7 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.